NCT05471856 - A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 24, 2023

Primary Completion Date

September 13, 2028

Study Completion Date

September 13, 2028

Conditions

Solid Tumors

Interventions

DRUG

BI 1703880

DRUG

Ezabenlimab

Trial Locations (13)

28050

RECRUITING

CIO Clara Campal, Madrid

46009

RECRUITING

Instituto Valenciano de Oncología, Valencia

46010

RECRUITING

Hospital Clínico de Valencia, Valencia

90067

RECRUITING

Valkyrie Clinical Trials, Los Angeles

06511

RECRUITING

Yale University School of Medicine, New Haven

07601

RECRUITING

John Theurer Cancer Center, Hackensack

277-8577

RECRUITING

National Cancer Center Hospital East, Chiba, Kashiwa

350-1298

NOT_YET_RECRUITING

Saitama Medical University International Medical Center, Saitama, Hidaka

135-8550

RECRUITING

Japanese Foundation for Cancer Research, Tokyo, Koto-ku

08035

RECRUITING

Hospital Vall d'Hebron, Barcelona

SW3 6JJ

RECRUITING

The Royal Marsden Hospital, Chelsea, London

OX3 7LE

RECRUITING

Churchill Hospital, Oxford

SM2 5PT

RECRUITING

The Royal Marsden Hospital, Sutton, Sutton